Argenx SE Reports Promising Trial Results for Efgartigimod, Boosting Stock Amid FDA Fast Track Designation
Argenx SE presents positive trial data for its treatment efgartigimod, showing significant improvement in patients with myositis and Sjogren’s disease.
One minute to read